These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23983234)

  • 1. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.
    Swinney DC
    J Biomol Screen; 2013 Dec; 18(10):1186-92. PubMed ID: 23983234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.
    Lee JA; Berg EL
    J Biomol Screen; 2013 Dec; 18(10):1143-55. PubMed ID: 24080259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic vs. target-based drug discovery for first-in-class medicines.
    Swinney DC
    Clin Pharmacol Ther; 2013 Apr; 93(4):299-301. PubMed ID: 23511784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How were new medicines discovered?
    Swinney DC; Anthony J
    Nat Rev Drug Discov; 2011 Jun; 10(7):507-19. PubMed ID: 21701501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of bioactive small molecule target through phenotypic screening.
    Cho YS; Kwon HJ
    Bioorg Med Chem; 2012 Mar; 20(6):1922-8. PubMed ID: 22153994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery.
    Fang Y
    J Pharmacol Toxicol Methods; 2013; 67(2):69-81. PubMed ID: 23340025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspective on the discovery and scientific impact of p38 MAP kinase.
    Young PR
    J Biomol Screen; 2013 Dec; 18(10):1156-63. PubMed ID: 23896688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving drug discovery with contextual assays and cellular systems analysis.
    Westwick JK; Lamerdin JE
    Methods Mol Biol; 2011; 756():61-73. PubMed ID: 21870220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of target identity and biology: implications for drug discovery and development.
    Patel AC
    J Biomol Screen; 2013 Dec; 18(10):1164-85. PubMed ID: 24080260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One size does not fit all: Challenging some dogmas and taboos in drug discovery.
    Chai CL; Mátyus P
    Future Med Chem; 2016 Jan; 8(1):29-38. PubMed ID: 26689236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-receptor interaction platforms and their applications for drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of medicines for rare diseases.
    Swinney DC; Xia S
    Future Med Chem; 2014 Jun; 6(9):987-1002. PubMed ID: 25068983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks.
    Swamidass SJ; Schillebeeckx CN; Matlock M; Hurle MR; Agarwal P
    J Biomol Screen; 2014 Jun; 19(5):782-90. PubMed ID: 24563424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2D and 3D cell microarrays in pharmacology.
    Gidrol X; Fouqué B; Ghenim L; Haguet V; Picollet-D'hahan N; Schaack B
    Curr Opin Pharmacol; 2009 Oct; 9(5):664-8. PubMed ID: 19520607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to protozoan drug discovery: phenotypic screening.
    Sykes ML; Avery VM
    J Med Chem; 2013 Oct; 56(20):7727-40. PubMed ID: 23927763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building predictive models for mechanism-of-action classification from phenotypic assay data sets.
    Berg EL; Yang J; Polokoff MA
    J Biomol Screen; 2013 Dec; 18(10):1260-9. PubMed ID: 24088371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of first-in-class drugs: origins and evolution.
    Eder J; Sedrani R; Wiesmann C
    Nat Rev Drug Discov; 2014 Aug; 13(8):577-87. PubMed ID: 25033734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-based assays: fuelling drug discovery.
    Michelini E; Cevenini L; Mezzanotte L; Coppa A; Roda A
    Anal Bioanal Chem; 2010 Sep; 398(1):227-38. PubMed ID: 20623273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update of novel screening methods for GPCR in drug discovery.
    Chen L; Jin L; Zhou N
    Expert Opin Drug Discov; 2012 Sep; 7(9):791-806. PubMed ID: 22716301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.